ArticleShock (Augusta, Ga.)2011
Epidermal growth factor improves survival and prevents intestinal injury in a murine model of pseudomonas aeruginosa pneumonia.
Article in Shock (Augusta, Ga.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 44 citations in OpenAlex.
- Sepsis and the diverse organ-gastrointestinal tract axis.World journal of critical care medicine · 2025Review
- Identification and Analysis of the Protective Role of Exosomes Derived from Umbilical Cord Mesenchymal Stem Cells in Sepsis-induced Intestinal Injury by Bioinformatics and Experimental Verification.Cell biochemistry and biophysics · 2025Article
- Crosstalk between lung and extrapulmonary organs in sepsis-related acute lung injury/acute respiratory distress syndrome.Annals of intensive care · 2025Review
- Gut-derived immune cells and the gut-lung axis in ARDS.Critical care (London, England) · 2024Review
- Beta-carotene regulates the biological activity of EGF in IEC6 cells by alleviating the inflammatory process.Cell cycle (Georgetown, Tex.) · 2022Article
- Gut-Lung Crosstalk in Sepsis-Induced Acute Lung Injury.Frontiers in microbiology · 2021Review
- Gut-liver crosstalk in sepsis-induced liver injury.Critical care (London, England) · 2020Review
- Targeting the gut to prevent sepsis from a cutaneous burn.JCI insight · 2020Article
- Esmolol inhibits inflammation and apoptosis in the intestinal tissue via the overexpression of NF-κB-p65 in the early stage sepsis rats.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Gut integrity in critical illness.Journal of intensive care · 2019Review
- Integrative Physiology of Pneumonia.Physiological reviews · 2018Review
- Gut-kidney crosstalk in septic acute kidney injury.Critical care (London, England) · 2018Review
- Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates inflammatory response and homeostasis of spleen and colon in experimental model of Pseudomonas aeruginosa pneumonia.Clinical nutrition (Edinburgh, Scotland) · 2017Article
- Sepsis reveals compartment-specific responses in intestinal proliferation and apoptosis in transgenic mice whose enterocytes re-enter the cell cycle.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- The intestinal microenvironment in sepsis.Biochimica et biophysica acta. Molecular basis of disease · 2017Review
- Myosin light chain kinase knockout improves gut barrier function and confers a survival advantage in polymicrobial sepsis.Molecular medicine (Cambridge, Mass.) · 2017Article
- New insights into the gut as the driver of critical illness and organ failure.Current opinion in critical care · 2017Review
- Epidermal Growth Factor Improves Intestinal Integrity and Survival in Murine Sepsis Following Chronic Alcohol Ingestion.Shock (Augusta, Ga.) · 2017Article
- Deletion of Nlrp3 Augments Survival during Polymicrobial Sepsis by Decreasing Autophagy and Enhancing Phagocytosis.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation.Biochimica et biophysica acta · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Mortality from pneumonia is mediated, in part, through extrapulmonary causes. Epidermal growth factor (EGF) has broad cytoprotective effects, including potent restorative properties in the injured intestine. The purpose of this study was to determine the efficacy of EGF treatment following Pseudomonas aeruginosa pneumonia. FVB/N mice underwent intratracheal injection of either P. aeruginosa or saline and were then randomized to receive either systemic EGF or vehicle beginning immediately or 24 h after the onset of pneumonia. Systemic EGF decreased 7-day mortality from 65% to 10% when initiated immediately after the onset of pneumonia and to 27% when initiated 24 h after the onset of pneumonia. Even though injury in pneumonia is initiated in the lungs, the survival advantage conferred by EGF was not associated with improvements in pulmonary pathology. In contrast, EGF prevented intestinal injury by reversing pneumonia-induced increases in intestinal epithelial apoptosis and decreases in intestinal proliferation and villus length. Systemic cytokines and kidney and liver function were unaffected by EGF therapy, although EGF decreased pneumonia-induced splenocyte apoptosis. To determine whether the intestine was sufficient to account for extrapulmonary effects induced by EGF, a separate set of experiments was done using transgenic mice with enterocyte-specific overexpression of EGF (IFABP-EGF [intestinal fatty acid-binding protein linked to mouse EGF] mice), which were compared with wild-type mice subjected to pneumonia. IFABP-EGF mice had improved survival compared with wild-type mice following pneumonia (50% vs. 28%, respectively, P < 0.05) and were protected from pneumonia-induced intestinal injury. Thus, EGF may be a potential adjunctive therapy for pneumonia, mediated in part by its effects on the intestine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.